TFX — Teleflex Incorporated stock price, charts and financials

QT56Teleflex Incorporated

Teleflex Incorporated (NYSE: TFX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
124.52
-1.07-0.85%
TFXQT56Teleflex Incorporated·NYSE
124.52-0.85%
News
Down 0.9% — Here's Why Teleflex (TFX) is a Strong Value Stock (zacks.com).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-23.29Insider Own0.90%Shs Outstand44.27MPerf Week-4.94%
Market Cap5.51BForward P/E11.37EPS next Y10.95Insider Trans0.00%Shs Float43.91MPerf Month-8.35%
Enterprise Value8.09BPEG-EPS next Q1.92Inst Own-Short Float9.16%Perf Quarter-1.95%
Income-1.03BP/S2.12EPS this Y130.93%Inst Trans-Short Ratio7.65Perf Half Y16.32%
Sales2.60BP/B1.90EPS next Y52.02%ROA-15.17%Short Interest4.02MPerf YTD2.03%
Book/sh65.62P/C18.37EPS next 5Y18.56%ROE-31.83%52W High144.99 -14.12%Perf Year-0.88%
Cash/sh6.78P/FCF14.85EPS past 3/5Y-ROIC1.30%52W Low100.18 24.30%Perf 3Y-41.63%
Dividend Est.1.36 (1.09%)EV/EBITDA-Sales past 3/5Y-10.62% -4.71%Gross Margin53.77%Volatility2.64% 2.92%Perf 5Y-66.56%
Dividend TTM1.36 (1.09%)EV/Sales3.11EPS Y/Y TTM-1673.65%Oper. Margin3.35%ATR (14)4.11Perf 10Y-33.89%
Dividend Ex-DateAug 14, 2026Quick Ratio2.12Sales Y/Y TTM-14.67%Profit Margin-39.58%RSI (14)28.88Recom2.52
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio2.60EPS Q/Q-52.82%SMA20-8.05%Beta0.82Target Price155.25
Payout-5.82%Debt/Eq0.87Sales Q/Q-27.02%SMA50-7.79%Rel Volume3.12Prev Close125.59
Employees15,500LT Debt/Eq0.84EarningsNov 05SMA2000.41%Avg Volume577.32KPrice124.52
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.37.36% 1.91%Net Debt/EBITDA-10.81Volume1,798,690Change-0.85%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-25-26ReiteratedNeedhamBuy$159$170
Aug-11-26ReiteratedUBSNeutral$145$158
Aug-10-26ReiteratedTruist SecuritiesHold$135$150
Jul-31-26ReiteratedNeedhamBuy$147$159
Jul-28-26InitiatedUBSNeutral$145
Jul-08-26InitiatedBMO CapitalOutperform$159
Jun-08-26UpgradePiper SandlerNeutralOverweight$245$160
May-08-26ReiteratedRaymond JamesOutperform$128$150
May-08-26ReiteratedMizuho SecuritiesNeutral$135$140
May-08-26UpgradeRBC CapitalSector PerformOutperform$135$155
Latest News· Times ET
Sep-16-26
Sep-15-26
Sep-14-26
Sep-11-26
Sep-08-26
Sep-07-26
Sep-04-26
Aug-28-26
Aug-26-26
Aug-25-26
Company

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,6001,9933,047
Cost of Goods Sold Incl. D&A1,2038721,345
Gross Profit1,3981,1211,703
Selling, General and Administrative Excl. Other944720995
Research and Development195145162
Other Operating Expense1710395
Operating Income86256151
Interest Expense12010084
Unusual Expense
Non-Operating Income (Expense)-377-1318
Net Income Before Taxes-4102575
Income Taxes-35-345
Consolidated Net Income-1,029-90670
Net Income From Continuing Operations-3765970
Net Income-1,029-90670
EPS (Recurring)-23.28-20.301.49
EPS (Basic, Before Extraordinaries)-23.28-20.301.49
EPS (Diluted)-23.29-20.251.48
EBITDA-238303434
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio120.26
Price To Sales Ratio2.112.762.75
Gross Margin53.7756.2555.89
Operating Margin3.3112.844.96
Net Margin-39.58-45.462.30
Shares Outstanding444547
Market Capitalization5,4795,4928,365
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$148.31$134.75$121.19$107.64$94.08 Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HAGGERTY GRETCHEN RDirectorAug 06 '25Buy114.7550057,3756,305Aug 07
Ryu JaewonDirectorAug 05 '25Buy115.001,500172,5003,727Aug 07
Kelly LiamChairman, President & CEOAug 05 '25Buy115.071,500172,60545,267Aug 07
Krakauer Andrew ADirectorAug 05 '25Buy115.251,000115,2507,192Aug 07
RANDLE STUART ADirectorAug 05 '25Buy115.861,000115,8607,547Aug 07
Duncan Candace HDirectorMay 05 '25Option Exercise123.044,833594,6529,561May 07
Klasko Stephen K. M.D.DirectorFeb 20 '25Option Exercise121.002,674323,5549,827Feb 21
Logue Daniel V.CVP, General Counsel & SectyFeb 20 '25Option Exercise121.001,620196,02014,328Feb 21
Kelly LiamChairman, President & CEOFeb 19 '25Option Exercise121.4136,4644,427,19963,556Feb 21
RANDLE STUART ADirectorAug 16 '24Sale238.932,674638,8995,496Aug 16
RANDLE STUART ADirectorAug 16 '24Option Exercise121.002,674323,5548,170Aug 16
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Sale225.007,4011,665,22510,050Mar 05
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Option Exercise135.147,4011,000,19717,451Mar 05
Logue Daniel V.CVP, General Counsel & SectyFeb 26 '24Option Exercise101.121,525154,20812,278Feb 28
Kelly LiamChairman, President & CEODec 27 '23Option Exercise101.8726,2562,674,57144,726Dec 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.